ArticleOncology letters2023
Conservative treatment of glassy cell cervical cancer: A case report.
Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Survival outcomes and prognostic factors in glassy cell carcinoma: a retrospective analysis of the SEER database from 1992 to 2021.Annals of medicine and surgery (2012) · 2025Article
- State of the art of cervical cancer treatment in rare histologies.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glassy cell carcinoma (GCC) constitutes a rare yet histologically aggressive subtype of cervical cancer known for its rapid proliferation and high risk of recurrence and metastasis. Due to its low prevalence, the medical literature lacks large retrospective and prospective studies, and thus, no standardized management has been defined. The recommended treatment for GCC is radical hysterectomy with bilateral pelvic lymphadenectomy; however, since it mainly affects young women of reproductive age, data in the literature suggest conservative management, such as radical trachelectomy. The present report describes the cases of 2 young patients treated conservatively with pelvic lymphadenectomy and radical trachelectomy for early-stage GCC of the cervix. The first patient was a 37-year-old patient who presented a 15-mm GCC tumor [International Federation of Gynecology and Obstetrics (FIGO) stage IB1], and the second patient was a 23-year-old patient who presented a 14-mm GCC tumor (FIGO stage IB1). The first patient presented early vaginal recurrence 3 months postoperatively, which was treated with concomitant pelvic chemoradiation (45 Gy) followed by vaginal and uterine brachytherapy (15 Gy). The second patient presented internal iliac nodal recurrence 1 year after treatment, which was treated by carboplatin-paclitaxel-Avastin-based chemotherapy, followed by laparoscopic paraaortic lymph node dissection and pelvic chemoradiation (45 Gy). Both patients were tumor-free after 5 and 6 years, respectively. Due to the aggressiveness of GCC of the cervix and its high risk of recurrence, conservative treatment should be considered cautiously and should not be the standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.